PET Scan in Patients With Neurocardiologic Disorders

NCT00001418 | Completed

• 2 other identifiers: 94018694-N-0186
• Study Type: observational
• Target: 335
• Locations: 1 country
• Sites: 1

Brief Summary

This study is designed to use PET scans in order to measure activity of the sympathetic nervous system. The sympathetic nervous system is the portion of the nervous system that maintains a normal supply of blood and fuel to organs during stressful situations. PET scan or Positron Emission Tomography is an advanced form of an X-ray. It is used to detect radioactive substances in the body. During this study researchers plan to inject small amounts of the radioactive drug fluorodopamine into patients. Fluorodopamine is very similar to the chemicals found in the sympathetic nervous system. It can attach to sympathetic nerve endings and allow researchers to view them with the aid of a PET scan. One area of the body with many sympathetic nerve endings is the heart. After giving a dose of fluorodopamine, researchers will be able to visualize all of the sympathetic nerve endings involved in the activity of the heart. In addition, this diagnostic test will help researchers detect abnormalities of the nervous system of patient's hearts.

Conditions

Autonomic Nervous System Diseases

Keywords

Sympathetic Nervous System; Dysautonomias; Postural Tachycardia Syndrome; Neurocardiogenic Syncope; Hypernoradrenergic Hypertension; Sympathectomy; Fluorodopamine; Positron Emission Tomography; Norepinephrine; Dopamine; Neurocardiologic Disorder

Eligibility Criteria

• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• The subjects are adult patients in one of the following diagnostic categories: coronary heart disease or chest pain and normal coronary arteries; myocardial dysfunction or failure; hypertension; or dysautonomia. Groups of appropriately matched healthy volunteers are studied concurrently as controls.

You may not qualify if:

• Minors are excluded.
• Subjects in whom anatomic factors complicate vascular access are excluded.
• Subjects who are not expected clinically to tolerate recumbency during the procedures are excluded.
• Pregnant or lactating women are excluded.
• Cardiology patients may be tested while off their usual medications. In this situation, the patients will be inpatients on the cardiology ward, managed clinically by staff of the Cardiology Branch, DIR, NHLBI. Hypertensives will be tested afer having discontinued anti-hypertensive medications for up to two weeks.
• Patients who must take medications continually in the following categories are excluded: anticoagulants, tricyclic antidepressants, barbiturates, aspirin, acetaminophen.
• Patients unable to discontinue nicotine or alcohol temporarily are excluded.

Sponsors & Collaborators

• National Institute of Neurological Disorders and Stroke (NINDS): lead

Study Sites (1)

National Institute of Neurological Disorders and Stroke (NINDS)

Bethesda, Maryland, 20892, United States

Location

MeSH Terms

Conditions

Autonomic Nervous System Diseases; Postural Orthostatic Tachycardia Syndrome; Syncope, Vasovagal

Condition Hierarchy (Ancestors)

Nervous System Diseases; Orthostatic Intolerance; Primary Dysautonomias; Syncope; Unconsciousness; Consciousness Disorders; Neurobehavioral Manifestations; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: observational
• Sponsor Type: NIH

Study Record Dates

• First Submitted: November 3, 1999
• First Posted: November 4, 1999
• Study Start: July 1, 1994
• Study Completion: August 1, 2004
• Last Updated: March 4, 2008

Record last verified: 2004-08

Locations

US (1)